Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single Product, Observational Registry Involving Patients Presenting With Locally Advanced or Metastatic Prostate Cancer Receiving Eligard as Androgen Deprivation Treatment.

NCT00992251 is registered in ClinicalTrials.gov with CMX Research as lead sponsor.

NCT NCT00992251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single Product, Observational Registry Involving Patients Presenting With Locally Advanced or Metastatic Prostate Cancer Receiving Eligard as Androgen Deprivation Treatment.
Lead sponsor
CMX Research
Phase
Observational
Overall status
Completed
Start date
August 31, 2009
Completion date
March 31, 2014
Enrollment
354 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate